DATA GRAPHICS | Finance
Data Bytes: cell and gene therapy IPOs make a strong showing in 3Q20
October 1, 2020 12:46 AM UTC
During the third quarter, seven cell and gene therapy companies brought in an aggregate $1.3 billion through IPOs, most of which priced within or above their proposed ranges.
T cell therapy developer AlloVir Inc. (NASDAQ:ALVR) led the pack in total amount raised and postmoney valuation, bringing in $317.7 million through its NASDAQ IPO at a valuation of $1.1 billion (see “AlloVir carries July’s IPO haul beyond $2.5B”). ...
BCIQ Company Profiles